Explore all companies

JCR Europe

Develops JR-141, a blood–brain barrier–penetrating enzyme replacement therapy for lysosomal storage disorders such as Hunter syndrome (MPS II).

Details

  • LSH Companies

Bargelaan 200, 2333 CW, Leiden

View company website